Loading clinical trials...
Loading clinical trials...
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
Conditions
Interventions
Nivolumab
Lirilumab
Locations
1
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
March 15, 2018
Primary Completion Date
July 6, 2021
Completion Date
July 6, 2026
Last Updated
June 18, 2025
NCT05075980
NCT05815927
NCT06736379
NCT05329532
NCT05059444
NCT06823479
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions